Overview

An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The primary objectives of this trial is to demonstrate that the fixed-dose combination of telmisartan 80mg plus amlodipine 5mg (T80/A5) is superior to amlodipine 5mg (A5) in reducing seated trough diastolic blood pressure (DBP) at 8 weeks.

Phase:

Phase 3

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Amlodipine
Telmisartan